Literature DB >> 11258956

Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism.

D S Park1, B Razani, A Lasorella, N Schreiber-Agus, R G Pestell, A Iavarone, M P Lisanti.   

Abstract

The c-Myc oncoprotein contributes to oncogenesis by activating and repressing a repertoire of genes involved in cellular proliferation, metabolism, and apoptosis. Increasing evidence suggests that the repressor function of c-Myc is critical for transformation. Therefore, identifying and characterizing Myc-repressed genes is imperative to understanding the mechanisms of Myc-induced tumorigenesis. Here, we employ NIH 3T3 cell lines harboring c-Myc-ER or N-Myc-ER to dissect the relationship between Myc activation and caveolin-1 expression. In this well-established inducible system, treatment with estrogen like molecules, such as tamoxifen, leads to activation of Myc, but in a tightly controlled fashion. Using this approach, we show that Myc activation induces the repression of caveolin-1 expression at the transcriptional level. We also provide two independent lines of evidence suggesting that caveolin-1 is a direct target of Myc: (i) the effect of Myc activation on caveolin-1 expression is independent of new protein synthesis, as revealed through the use of cycloheximide; and (ii) Myc-mediated repression of the caveolin-1 promoter is dependent on an intact INR sequence. Moreover, we show that expression of caveolin-1, via an adenoviral vector approach, can suppress cell transformation that is mediated by Myc activation. In support of these observations, treatment with an adenoviral vector harboring anti-sense caveolin-1 specifically potentiates transformation induced by Myc activation. Taken together, our results indicate that caveolin-1 is a direct target of Myc repression, and they also provide evidence for an additional mechanism by which Myc repression can elicit a malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11258956     DOI: 10.1021/bi002787b

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  19 in total

1.  Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status.

Authors:  Tianhong Li; Federica Sotgia; Magalis A Vuolo; Maomi Li; Wan Cai Yang; Richard G Pestell; Joseph A Sparano; Michael P Lisanti
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

2.  Wild-type APC regulates caveolin-1 expression in human colon adenocarcinoma cell lines via FOXO1a and C-myc.

Authors:  Upal K Basu Roy; Rebecca S Henkhaus; Natalia A Ignatenko; Jessica Mora; Kimberly E Fultz; Eugene W Gerner
Journal:  Mol Carcinog       Date:  2008-12       Impact factor: 4.784

3.  N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.

Authors:  Michael B Armstrong; Rajen J Mody; D Christian Ellis; Adam B Hill; David A Erichsen; Daniel S Wechsler
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

4.  Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival.

Authors:  Zhi Zhao; Fang-Hai Han; Shi-Bin Yang; Li-Xin Hua; Jian-Hai Wu; Wen-Hua Zhan
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

5.  Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells.

Authors:  Ubaldo E Martinez-Outschoorn; Renee M Balliet; Dayana B Rivadeneira; Barbara Chiavarina; Stephanos Pavlides; Chenguang Wang; Diana Whitaker-Menezes; Kristin M Daumer; Zhao Lin; Agnieszka K Witkiewicz; Neal Flomenberg; Anthony Howell; Richard G Pestell; Erik S Knudsen; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2010-08-28       Impact factor: 4.534

6.  HIV infection upregulates caveolin 1 expression to restrict virus production.

Authors:  Shanshan Lin; Xiao Mei Wang; Peter E Nadeau; Ayalew Mergia
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

7.  Clinicopathological significance of caveolin-1 expression by cancer-associated fibroblasts in lung adenocarcinoma.

Authors:  Kei Shimizu; Keisuke Kirita; Keiju Aokage; Motohiro Kojima; Tomoyuki Hishida; Takeshi Kuwata; Satoshi Fujii; Atsushi Ochiai; Kazuhito Funai; Junji Yoshida; Masahiro Tsuboi; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-22       Impact factor: 4.553

8.  Direct control of caveolin-1 expression by FOXO transcription factors.

Authors:  A Pieter J van den Heuvel; Almut Schulze; Boudewijn M T Burgering
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

9.  Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation.

Authors:  Franco Capozza; Terence M Williams; William Schubert; Steve McClain; Boumediene Bouzahzah; Federica Sotgia; Michael P Lisanti
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

10.  Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia.

Authors:  Hyangkyu Lee; David S Park; Babak Razani; Robert G Russell; Richard G Pestell; Michael P Lisanti
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.